LDHC and ovarian serous carcinoma: As aforementioned, to the best of our knowledge, the immunogenicity of LDHC has been investigated in one study only that demonstrated the presence of LDHC-peptide reactive T cells in the ascites of three of five patients with high-grade serous ovarian carcinoma [33].